Effectiveness of ChAdOx1-S COVID-19 Booster Vaccination against the Omicron and Delta variants in England

Freja Kirsebom, Nick Andrews, Ruchira Sachdeva, Julia Stowe, Mary Ramsay, Jamie Lopez Bernal
doi: https://doi.org/10.1101/2022.04.29.22274483

Article Information

doi 
https://doi.org/10.1101/2022.04.29.22274483
History 
  • May 1, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Freja Kirsebom, PhD1,
  2. Nick Andrews, PhD1,2,
  3. Ruchira Sachdeva,
  4. Julia Stowe, PhD1,
  5. Mary Ramsay, MBBS, FFPH1,2 and
  6. Jamie Lopez Bernal, PhD, MBBS1,2,3,*
  1. 1UK Health Security Agency, London, United Kingdom
  2. 2NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine, London, United Kingdom
  3. 3NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London, United Kingdom
  1. ↵*Corresponding author; email: jamie.lopezbernal2{at}phe.gov.uk
Back to top
Posted May 01, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Effectiveness of ChAdOx1-S COVID-19 Booster Vaccination against the Omicron and Delta variants in England
Freja Kirsebom, Nick Andrews, Ruchira Sachdeva, Julia Stowe, Mary Ramsay, Jamie Lopez Bernal
medRxiv 2022.04.29.22274483; doi: https://doi.org/10.1101/2022.04.29.22274483
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area